Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 10/20 | 0.80 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527812 | 0.89 | TBXA2R (1.00) | TBXA2RTBXAS1 | |
| SCHEMBL15052627 | 0.88 | TBXA2R (0.76) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL9248933 | 0.86 | TBXA2R (0.80) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL15052203 | 0.86 | TBXA2R (0.74) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL15052383 | 0.86 | TBXA2R (0.79) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL15052947 | 0.86 | TBXA2R (0.79) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL15052326 | 0.86 | TBXA2R (0.79) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL15052127 | 0.86 | TBXA2R (0.73) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL527399 | 0.84 | TBXA2R (0.76) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL15078829 | 0.84 | TBXA2R (0.76) | TBXA2RTBXAS1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927586-B2 | Thromboxane A2 (TP) receptor antagonists | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130190370-A1 | Novel Tetrahydronaphalene Antagonists to the Thromboxane A2 (TP) Receptor | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130165488-A1 | Novel Thromboxane A2 (TP) Receptor Antagonists | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190370-A1 | Novel Tetrahydronaphalene Antagonists to the Thromboxane A2 (TP) Receptor | TBXA2R, PTGIR, PTGFR | TBXA2R 1/4885TBXAS1 6/4885HDAC8 4093/4885 |
| US-20130165488-A1 | Novel Thromboxane A2 (TP) Receptor Antagonists | TBXA2R, TBXAS1, PTGIR | TBXA2R 1/4885TBXAS1 2/4885HDAC8 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.